Upgrade to SI Premium - Free Trial

Goldman Sachs Reiterates Buy Rating on Summit Therapeutics plc (SMMT)

September 29, 2026 5:38 AM
Goldman Sachs analyst Satoru Ogawa reiterated a Buy rating and $41.00 price target on Summit Therapeutics plc (NASDAQ: SMMT)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments